CDK4/6 inhibitor combination could overcome drug resistance in advanced prostate cancer

With an estimated 1.5 million new cases and 397,000 deaths worldwide, prostate cancer is the world's second most frequent cancer and the fifth leading cause of cancer death among men in 2022. Hormone therapy based on the inhibition of androgen receptor signaling (ARPi) is the mainstay of treatment for metastatic prostate cancer (mPC). However, cancer drug resistance ultimately arises, highlighting the need for more effective therapeutic strategies.

👉 Full Story